Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s disease candidate KW-6356, a drug in the adenosine A2A receptor antagonist class.